2.1 million infections were reported in the continent in 2015, two thirds of which occurred in sub-Saharan Africa.
A small trial, known as HVTN100, initially took place in South Africa in 2015 to test the safety and strength of immunity the vaccine could provide, ahead of any large-scale testing in affected populations.Follow @newslexpoint
Two-hundred and fifty-two healthy volunteers were enrolled to receive either the vaccine, known as ALVAC – HIV/gp120.
“This was precautionary to see if the vaccine looks promising,” CNN reports Linda Gail Bekker, deputy director of the Desmond Tutu HIV Centre in Cape Town, South Africa, and president-elect of the International AIDS Society, who is leading the vaccine trials, as saying.
The vaccine stems from a landmark trial in Thailand in 2009 that was the first to show any protection against the killer virus, with 31% protection against the virus. This was enough to get experts in the field excited after years with no success.
The vaccine was improved for use in the higher-risk populations of sub-Saharan Africa, where a different subtype of the virus also exists.
5,400 people across four sites in South Africa will receive the vaccine in November and run for three years.
Source: CCTV Africa
- An Interview with Dr Gallo About The Cause Of AIDS
- Did Dr.Robert Gallo Create HIV/AIDS?
- Nigerian Proffessor Made Antiviral Drug that cures HIV AIDS
Please use the button below to contribute to Newslex Point, Inc. using a credit card or via PayPal.